Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant

Vittorio Pengo, Sophie Testa, Ida Martinelli, Angelo Ghirarduzzi, Cristina Legnani, Paolo Gresele, Serena M. Passamonti, Elisa Bison, Gentian Denas, Seena Padayattil Jose, Alessandra Banzato, Amelia Ruffatti

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Among the so called antiphospholipid (aPL) antibodies Lupus Anticoagulant (LAC) is considered the strongest risk factor for thromboembolic events. In individuals without a previous thromboembolic event (carriers), LAC is a risk factor when associated with the presence of anticardiolipin (aCL) and aβ2-Glycoprotein I (aβ2GPI) antibodies. On the other hand, data on carriers of isolated LAC positivity are sparse and inconclusive. The aim of this study was to prospectively determine the incidence of thrombosis in a cohort of carriers of isolated LAC positivity. One-hundred seventy-nine carriers of LAC confirmed twelve weeks apart and in a reference laboratory were studied. During a total follow up of 552 person-years, there were seven thromboembolic events (1.3% person-y). All the seven patients had at least one adjunctive major risk factor for thrombosis. The cumulative incidence of thromboembolic events was 3.1% (95% CI 0.6-5.6) after 2 years, and 5.9% (95% CI 1.2-10.6) after 5 and 10 years. On a multivariate regression analysis considering age, sex, autoimmune disease, risk factors for arterial and venous thrombosis, use of aspirin, only age was found to be an independent predictor of thromboembolic events (HR = 1.1, 95% CI 1.0-1.2, p = 0.02). These data might be relevant in clinical practice and underline the importance of differentiating LAC carriers in terms of isolated positivity or positivity associated with the presence of antibodies to aCL and β2-glycoprotein I.

Original languageEnglish
Pages (from-to)46-49
Number of pages4
JournalThrombosis Research
Volume135
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Lupus Coagulation Inhibitor
Incidence
Glycoproteins
Thrombosis
Anticardiolipin Antibodies
Antiphospholipid Antibodies
Venous Thrombosis
Aspirin
Autoimmune Diseases
Multivariate Analysis
Regression Analysis
Antibodies

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. / Pengo, Vittorio; Testa, Sophie; Martinelli, Ida; Ghirarduzzi, Angelo; Legnani, Cristina; Gresele, Paolo; Passamonti, Serena M.; Bison, Elisa; Denas, Gentian; Jose, Seena Padayattil; Banzato, Alessandra; Ruffatti, Amelia.

In: Thrombosis Research, Vol. 135, No. 1, 01.01.2015, p. 46-49.

Research output: Contribution to journalArticle

Pengo, V, Testa, S, Martinelli, I, Ghirarduzzi, A, Legnani, C, Gresele, P, Passamonti, SM, Bison, E, Denas, G, Jose, SP, Banzato, A & Ruffatti, A 2015, 'Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant', Thrombosis Research, vol. 135, no. 1, pp. 46-49. https://doi.org/10.1016/j.thromres.2014.10.013
Pengo, Vittorio ; Testa, Sophie ; Martinelli, Ida ; Ghirarduzzi, Angelo ; Legnani, Cristina ; Gresele, Paolo ; Passamonti, Serena M. ; Bison, Elisa ; Denas, Gentian ; Jose, Seena Padayattil ; Banzato, Alessandra ; Ruffatti, Amelia. / Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. In: Thrombosis Research. 2015 ; Vol. 135, No. 1. pp. 46-49.
@article{4015cca520e1484b90e6bafc50aa3ebc,
title = "Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant",
abstract = "Among the so called antiphospholipid (aPL) antibodies Lupus Anticoagulant (LAC) is considered the strongest risk factor for thromboembolic events. In individuals without a previous thromboembolic event (carriers), LAC is a risk factor when associated with the presence of anticardiolipin (aCL) and aβ2-Glycoprotein I (aβ2GPI) antibodies. On the other hand, data on carriers of isolated LAC positivity are sparse and inconclusive. The aim of this study was to prospectively determine the incidence of thrombosis in a cohort of carriers of isolated LAC positivity. One-hundred seventy-nine carriers of LAC confirmed twelve weeks apart and in a reference laboratory were studied. During a total follow up of 552 person-years, there were seven thromboembolic events (1.3{\%} person-y). All the seven patients had at least one adjunctive major risk factor for thrombosis. The cumulative incidence of thromboembolic events was 3.1{\%} (95{\%} CI 0.6-5.6) after 2 years, and 5.9{\%} (95{\%} CI 1.2-10.6) after 5 and 10 years. On a multivariate regression analysis considering age, sex, autoimmune disease, risk factors for arterial and venous thrombosis, use of aspirin, only age was found to be an independent predictor of thromboembolic events (HR = 1.1, 95{\%} CI 1.0-1.2, p = 0.02). These data might be relevant in clinical practice and underline the importance of differentiating LAC carriers in terms of isolated positivity or positivity associated with the presence of antibodies to aCL and β2-glycoprotein I.",
author = "Vittorio Pengo and Sophie Testa and Ida Martinelli and Angelo Ghirarduzzi and Cristina Legnani and Paolo Gresele and Passamonti, {Serena M.} and Elisa Bison and Gentian Denas and Jose, {Seena Padayattil} and Alessandra Banzato and Amelia Ruffatti",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.thromres.2014.10.013",
language = "English",
volume = "135",
pages = "46--49",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant

AU - Pengo, Vittorio

AU - Testa, Sophie

AU - Martinelli, Ida

AU - Ghirarduzzi, Angelo

AU - Legnani, Cristina

AU - Gresele, Paolo

AU - Passamonti, Serena M.

AU - Bison, Elisa

AU - Denas, Gentian

AU - Jose, Seena Padayattil

AU - Banzato, Alessandra

AU - Ruffatti, Amelia

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Among the so called antiphospholipid (aPL) antibodies Lupus Anticoagulant (LAC) is considered the strongest risk factor for thromboembolic events. In individuals without a previous thromboembolic event (carriers), LAC is a risk factor when associated with the presence of anticardiolipin (aCL) and aβ2-Glycoprotein I (aβ2GPI) antibodies. On the other hand, data on carriers of isolated LAC positivity are sparse and inconclusive. The aim of this study was to prospectively determine the incidence of thrombosis in a cohort of carriers of isolated LAC positivity. One-hundred seventy-nine carriers of LAC confirmed twelve weeks apart and in a reference laboratory were studied. During a total follow up of 552 person-years, there were seven thromboembolic events (1.3% person-y). All the seven patients had at least one adjunctive major risk factor for thrombosis. The cumulative incidence of thromboembolic events was 3.1% (95% CI 0.6-5.6) after 2 years, and 5.9% (95% CI 1.2-10.6) after 5 and 10 years. On a multivariate regression analysis considering age, sex, autoimmune disease, risk factors for arterial and venous thrombosis, use of aspirin, only age was found to be an independent predictor of thromboembolic events (HR = 1.1, 95% CI 1.0-1.2, p = 0.02). These data might be relevant in clinical practice and underline the importance of differentiating LAC carriers in terms of isolated positivity or positivity associated with the presence of antibodies to aCL and β2-glycoprotein I.

AB - Among the so called antiphospholipid (aPL) antibodies Lupus Anticoagulant (LAC) is considered the strongest risk factor for thromboembolic events. In individuals without a previous thromboembolic event (carriers), LAC is a risk factor when associated with the presence of anticardiolipin (aCL) and aβ2-Glycoprotein I (aβ2GPI) antibodies. On the other hand, data on carriers of isolated LAC positivity are sparse and inconclusive. The aim of this study was to prospectively determine the incidence of thrombosis in a cohort of carriers of isolated LAC positivity. One-hundred seventy-nine carriers of LAC confirmed twelve weeks apart and in a reference laboratory were studied. During a total follow up of 552 person-years, there were seven thromboembolic events (1.3% person-y). All the seven patients had at least one adjunctive major risk factor for thrombosis. The cumulative incidence of thromboembolic events was 3.1% (95% CI 0.6-5.6) after 2 years, and 5.9% (95% CI 1.2-10.6) after 5 and 10 years. On a multivariate regression analysis considering age, sex, autoimmune disease, risk factors for arterial and venous thrombosis, use of aspirin, only age was found to be an independent predictor of thromboembolic events (HR = 1.1, 95% CI 1.0-1.2, p = 0.02). These data might be relevant in clinical practice and underline the importance of differentiating LAC carriers in terms of isolated positivity or positivity associated with the presence of antibodies to aCL and β2-glycoprotein I.

UR - http://www.scopus.com/inward/record.url?scp=84922552998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922552998&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2014.10.013

DO - 10.1016/j.thromres.2014.10.013

M3 - Article

C2 - 25456002

AN - SCOPUS:84922552998

VL - 135

SP - 46

EP - 49

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 1

ER -